scholarly journals Long non-coding RNA GAS5 and ZFAS1 are prognostic markers involved in translation targeted by miR-940 in prostate cancer

Oncotarget ◽  
2017 ◽  
Vol 9 (1) ◽  
pp. 1048-1062 ◽  
Author(s):  
Xin Chen ◽  
Chao Yang ◽  
Shengli Xie ◽  
Edwin Cheung
Keyword(s):  
Prostate Cancer ◽  
Prognostic Markers ◽  
Non Coding Rna ◽  
Long Non Coding Rna

scholarly journals RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies

Diagnostics ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. 60 ◽  
Author(s):  
Marvin Lim ◽  
Anne-Marie Baird ◽  
John Aird ◽  
John Greene ◽  
Dhruv Kapoor ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Biology ◽  
Prognostic Markers ◽  
Circular Rna ◽  
Liquid Biopsies ◽  
Non Coding Rna ◽  
Cancer Initiation ◽  
Long Non Coding Rna ◽  
Active Investigation

The treatment landscape of prostate cancer has evolved rapidly over the past five years. The explosion in treatment advances has been witnessed in parallel with significant progress in the field of molecular biomarkers. The advent of next-generation sequencing has enabled the molecular profiling of the genomic and transcriptomic architecture of prostate and other cancers. Coupled with this, is a renewed interest in the role of non-coding RNA (ncRNA) in prostate cancer biology. ncRNA consists of several different classes including small non-coding RNA (sncRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). These families are under active investigation, given their essential roles in cancer initiation, development and progression. This review focuses on the evidence for the role of RNAs in prostate cancer, and their use as diagnostic and prognostic markers, and targets for treatment in this disease.

scholarly journals Long non‐coding RNA NORAD promotes the prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone metastasis of prostate cancer

2021 ◽  
Vol 40 (1) ◽  
Author(s):  
Chuan-yi Hu ◽  
Juan Chen ◽  
Xin-hua Qin ◽  
Pan You ◽  
Jie Ma ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Bone Metastasis ◽  
Stromal Cells ◽  
Bone Marrow Stromal Cells ◽  
Marrow Stromal Cells ◽  
Downstream Target ◽  
Non Coding Rna ◽  
Target Molecules ◽  
Long Non Coding Rna

Abstract Background Bone metastasis is the leading cause of mortality and reduced quality of life in patients with metastatic prostate cancer (PCa). Long non-coding RNA activated by DNA damage (NORAD) has been observed to have an abnormal expression in various cancers. This article aimed to explore the molecular mechanism underlying the regulatory role of NORAD in bone metastasis of PCa. Methods NORAD expression in clinical PCa tissues and cell lines was detected with the application of qRT-PCR. Cancer cells were then transfected with plasmids expressing NORAD, after which Transwell assay and CCK-8 assay were carried out to detect proliferation, migration, and bone metastasis of PCa. NORAD downstream target molecules were screened through bioinformatics analysis, followed by further verification using dual luciferase assay. Extracellular vesicles (EVs) were labeled with PKH67 and interacted with bone marrow stromal cells. The gain- and loss-function method was applied to determine the internalization and secretion of PCa cells-derived EVs under the intervention of downstream target molecules or NORAD. Results PCa tissues and cell lines were observed to have a high expression of NORAD, particularly in tissues with bone metastasis. NORAD knockdown resulted in reduced secretion and internalization of EVs, and suppressed proliferation, migration, and bone metastasis of PCa cells. It was indicated that NORAD interacted with miR-541-3p, leading to the upregulation of PKM2. Forced expression of PKM2 promoted the transfer of PKH67-labeled EVs to bone marrow stromal cells. Conclusions NORAD might serve as a ceRNA of miR-541-3p to promote PKM2 expression, thereby enhancing the development of bone metastasis in PCa by promoting internalization and transfer of EVs of cancer cells, providing an insight into a novel treatment for the disorder.

scholarly journals Detecting long non-coding RNA biomarkers in prostate cancer liquid biopsies: Hype or hope?

2018 ◽  
Vol 3 (2) ◽  
pp. 64-74 ◽  
Author(s):  
Hetty Helsmoortel ◽  
Celine Everaert ◽  
Nicolaas Lumen ◽  
Piet Ost ◽  
Jo Vandesompele
Keyword(s):  
Prostate Cancer ◽  
Liquid Biopsies ◽  
Non Coding Rna ◽  
Long Non Coding Rna ◽  
Rna Biomarkers

scholarly journals TUG1 promotes prostate cancer progression by acting as a ceRNA of miR-26a

2018 ◽  
Vol 38 (5) ◽  
Author(s):  
Bin Yang ◽  
Xiaodi Tang ◽  
Zhixin Wang ◽  
Daju Sun ◽  
Xin Wei ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Migration And Invasion ◽  
Tumor Cell Migration ◽  
Real Time Quantitative Pcr ◽  
Non Coding Rna ◽  
Key Aspects ◽  
And Function ◽  
First Time ◽  
Long Non Coding Rna

Previous studies have demonstrated that taurine-upregulated gene 1 (TUG1) was aberrantly expressed and involved in multiple types of cancer; however, the expression profile and potential role of TUG1 in prostate cancer (PCa) remains unclear. The aim of the present study was to evaluate the expression and function of TUG1 in PCa. In the present study, we analyzed TUG1 expression levels of PCa patients in tumor and adjacent normal tissue by real-time quantitative PCR. Knockdown of TUG1 by RNAi was performed to explore its roles in cell proliferation, migration, and invasion. Here we report, for the first time, that TUG1 promotes tumor cell migration, invasion, and proliferation in PCa by working in key aspects of biological behaviors. TUG1 could negatively regulate the expression of miR-26a in PCa cells. The bioinformatics prediction revealed putative miR-26a-binding sites within TUG1 transcripts. In conclusion, our study suggests that long non-coding RNA (lncRNA) TUG1 acts as a functional oncogene in PCa development.

Long non-coding RNA SNHG6 is upregulated in prostate cancer and predicts poor prognosis

2019 ◽  
Vol 46 (3) ◽  
pp. 2771-2778 ◽  
Author(s):  
Youji Yan ◽  
Zhongjun Chen ◽  
Yu Xiao ◽  
Xinghuan Wang ◽  
Kaiyu Qian
Keyword(s):  
Prostate Cancer ◽  
Poor Prognosis ◽  
Non Coding Rna ◽  
Long Non Coding Rna
Sign in / Sign up

Export Citation Format

Share Document